Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745319 | 0.84 | CYP2D6 (0.60) | POLBMEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL14068495 | 0.83 | CYP2C19 (0.70) | POLBMEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL3704422 | 0.82 | CYP2C19 (0.74) | POLBMEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL1241370 | 0.81 | BCHE (0.64) | ALDH1A1SMN1; SMN2KDM4EATMEGFR | |
| Water SCHEMBL28295097 | 0.81 | CYP2C19 (0.72) | POLBMEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL3175221 | 0.79 | CYP2C19 (0.80) | POLBMEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL1241355 | 0.78 | LTA4H (0.64) | ALDH1A1SMN1; SMN2KDM4EATMEGFR | |
| SCHEMBL1463825 | 0.78 | POLB (0.61) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1852796 | 0.77 | SMN1; SMN2 (0.74) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2478030 | 0.76 | KMT2A (0.61) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288380-B2 | Thiophenediamine derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288380-B2 | Thiophenediamine derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-2292611-B1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-8198271-B2 | Thiophenediamine derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110077244-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-2292611-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292611-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009142321-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | 参天製薬株式会社 (JP) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | CBR1, NAT1, PRMT1 | POLB 2414/4885MEN1 2127/4885KMT2A 2284/4885 |
| US-20110077244-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | HNMT, HRH4, CHRM1 | POLB 3976/4885MEN1 1744/4885KMT2A 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.